Watch Live

Tweet TWEET

Watson's Generic Lysteda® Receives FDA Approval

               Watson's Generic Lysteda® Receives FDA Approval

PR Newswire

PARSIPPANY, N.J., Jan. 3, 2013

PARSIPPANY, N.J., Jan. 3, 2013 /PRNewswire/ --Watson Pharmaceuticals, Inc.
(NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. –
Florida has received approval from the U.S. Food and Drug Administration (FDA)
on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets,
the generic equivalent to Ferring Pharmaceuticals' Lysteda®.

Watson intends to begin shipping the product immediately. Lysteda® is
indicated for the treatment of cyclic heavy menstrual bleeding. Ferring B.V.
has filed lawsuits against Watson, alleging that Watson's ANDA product
infringes U.S. Patent Nos. 7,947,739, 8,022,106, and 8,273,795. The
litigations remain pending.

For the 12 months ending November 30, 2012, Lysteda® had total U.S. sales of
approximately $25 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals,Inc. (NYSE: WPI) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and distributing
generic, brand and biosimilar products. The Company has global and U.S.
headquarters in Parsippany, New Jersey, USA, and international headquarters in
Zug, Switzerland.

Watson is the world's third-largest generics prescription drug manufacturer,
with more than 750 products marketed globally through operations in more than
60 countries. Watson's global branded pharmaceutical business develops and
markets products principally in Urology and Women's Health, and iscommitted
to developing and marketing biosimilars products in Women's Health, Oncology
and other therapeutic categories. In addition, Watson is the fourth-largest
U.S. generic pharmaceutical product distributor through its Anda, Inc.
business, and also develops and out-licenses generic pharmaceutical products
outside of the U.S. through its Medis third-party business. Watson has
announced that it will adopt a new global name – Actavis – effective in 2013.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Watson's current perspective of
existing information as of the date of this release. It is important to note
that Watson's goals and expectations are not predictions of actual
performance. Actual results may differ materially from Watson's current
expectations depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others, the
difficulty of predicting the timing and outcome of the pending patent
litigation and risks that an adverse outcome in such litigation could render
Watson liable for substantial damages; the impact of competitive products and
pricing; the timing and success of product launches; difficulties or delays in
manufacturing; the availability and pricing of third party sourced products
and materials; successful compliance with FDA and other governmental
regulations applicable to Watson and its third party manufacturers'
facilities, products and/or businesses; changes in the laws and regulations,
including Medicare and Medicaid, affecting among other things, pricing and
reimbursement of pharmaceutical products; and such other risks and
uncertainties detailed in Watson's periodic public filings with the Securities
and Exchange Commission, including but not limited to Watson's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012 and Watson's
Annual Report on Form 10-K for the year ended December 31, 2011. Except as
expressly required by law, Watson disclaims any intent or obligation to update
these forward-looking statements.

Lysteda® is a registered trademark of Ferring B.V.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Media:
          Charlie Mayr
          (862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.

Website: http://www.watson.com
 
Press spacebar to pause and continue. Press esc to stop.